3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Unknown
1
Not yet recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Dermatologic
1
Conditions
Leukemia, Myeloid, Acute
133
Precursor Cell Lymphoblastic Leukemia-Lymphoma
115
Myelodysplastic Syndromes
111
Leukemia, Lymphocytic, Chronic, B-Cell
101
Lymphoma, Non-Hodgkin
97
Hodgkin Disease
94
Leukemia
85
Multiple Myeloma
84
Lymphoma
71
Lymphoma, Mantle-Cell
66
Lymphoma, Follicular
66
Lymphoma, Large B-Cell, Diffuse
63
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
60
Myeloproliferative Disorders
58
Lymphoma, B-Cell, Marginal Zone
57
Burkitt Lymphoma
52
Leukemia, Myelomonocytic, Chronic
51
Congenital Abnormalities
50
Leukemia, Myeloid, Chronic-Phase
49
Lymphoma, Large-Cell, Immunoblastic
45
Leukemia, Myeloid, Accelerated Phase
42
Hematologic Neoplasms
42
Anemia, Refractory, with Excess of Blasts
40
Graft vs Host Disease
39
Primary Myelofibrosis
36
Waldenstrom Macroglobulinemia
33
Neoplasms, Plasma Cell
32
Blast Crisis
32
Lymphoma, T-Cell, Cutaneous
30
Recurrence
29
Interventions
Mycophenolic Acid
2
vedolizumab
1
bavituximab
1
Ursodeoxycholic Acid
1
Steroids
1
Sorafenib
1
Sofosbuvir
1
Ribavirin
1
Prednisone
1
Photopheresis
1
Methylprednisolone Hemisuccinate
1
Methylprednisolone
1
Methoxsalen
1
Infliximab
1
Azathioprine
1
Adrenal Cortex Hormones
1
3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Hepatitis
×
Mycophenolic Acid
×
Clear all
NCT07619898
2026-06-02
PHOENIX-ECP
Therakos LLC
Phase 2
Not yet recruiting
112 enrolled
NCT04810156
2022-12-14
I-HEP
Herlev Hospital
Phase 2
Unknown
60 enrolled